TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04474210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 tablets orally.
Study: NCT03483870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: 2 mL of 2 mg granisetron IV injection
Study: NCT02749942

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoRIC: Remote Ischemic Conditioning
Description: 4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AutoRIC: Sham device treatment
Description: 4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada
Study: NCT01024491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: daily dose of paroxetine 15mg for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: active daily treatment with paroxetine 20 mg
Study: NCT01031108

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.

Intervention type: DRUG
Group type: OTHER
Intervention: SRT2104
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.

Intervention type: DRUG
Group type: OTHER
Intervention: SRT2104
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study: NCT01694667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
Study: NCT02791204

Intervention type: DEVICE
Intervention: SPECT/CT imaging
Description: Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
Study: NCT03176407

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HemoPill acute
Description: Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
Study: NCT01024491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: active daily treatment with placebo
Study: NCT02262078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite Inhalation Solution
Description: 90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be administered (by inhalation) to participants prior to exercise.
Study: NCT03529097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: 2 liters of 0.9% NaCl IV fluids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optalgin, Voltaren, Morphine
Description: Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optalgin, Voltaren, Morphine
Description: Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
Study: NCT01471418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT with 18-FDG
Description: FDG uptake
Study: NCT02630017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD methylphenidate first, placebo second
Description: double-blind, counter-balanced administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD placebo first, methylphenidate second
Description: double-blind, counter-balanced administration
Study: NCT03591588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
Study: NCT04186377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
Description: Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
Description: Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S26E
Description: Daily application of S26E extract on wound site
Study: NCT01903902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please Drug-eluting balloon
Description: Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length \< 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
Study: NCT04081532

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical removal of superficial peritoneal endometriosis
Description: In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
Study: NCT01772199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK239512
Description: White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White to almost white, round tablets. Once daily orally.
Study: NCT01473069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853, ketoconazole
Description: JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: JTK-853 Tablets or Placebo, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: JTK-853 Tablets or Placebo, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: JTK-853 Tablets or Placebo, twice a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JTK-853 or Placebo
Description: JTK-853 Tablets or Placebo, twice a day for 14 days
Study: NCT01020097

Intervention type: DRUG
Group type: OTHER
Intervention: fluorine F18 EF5
Description: Given IV

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immunohistochemistry staining method
Description: Correlative study

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Description: Correlative study

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron Emission tomography
Description: Undergo scan
Study: NCT03556852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
Study: NCT00958048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation
Description: CPAP, BiPAP
Study: NCT02761499

Intervention type: DEVICE
Intervention: U-Motion II+ Acetabular System
Description: U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
Study: NCT02383693

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation
Study: NCT02630017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-ADHD methylphenidate first, placebo second
Description: double-blind, counter-balanced administration
Study: NCT03677167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking on a treadmill
Description: Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking on a treadmill
Description: Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
Study: NCT04089202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eConsult
Description: Completion of electronic consult utilizing data collected from flash glucose monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
Study: NCT03279367

Intervention type: DIAGNOSTIC_TEST
Intervention: Objective speech response detection
Description: Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
Study: NCT05309057

Intervention type: DIETARY_SUPPLEMENT
Intervention: Intermittent Fasting
Description: Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
Study: NCT02964468

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3DCRT treatment (sequential boost)
Description: Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose Escalation Intensity Modulated Radiotherapy treatment
Description: Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers.
Study: NCT03398057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
Study: NCT02814409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
Description: IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Tenecteplase
Description: IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
Study: NCT02176694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
Study: NCT02309515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM
Study: NCT02684656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: Hemodialysis \>/=4h
Study: NCT02630017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-ADHD placebo first, methylphenidate second
Study: NCT05945056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frog Leg Exercise
Description: The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy(Transcutaneous Electrical Nerve Stimulator)
Description: TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy(Transcutaneous Electrical Nerve Stimulator)
Description: TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
Study: NCT03454516

Intervention type: OTHER
Group type: OTHER
Intervention: telemonitoring
Description: the follow-up of the patient will be performed with Telemonitoring
Study: NCT04066569

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam
Description: After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)
Description: After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo.
Study: NCT02684656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: Hemodiafiltration \>/=4h, \> 20l convection
Study: NCT03000543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
Study: NCT03887065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-4
Description: Novel small human peptide derived from erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-4
Description: Novel small human peptide derived from erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-4
Description: Novel small human peptide derived from erythropoietin
Study: NCT03943680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRGF
Description: After tooth extraction, the socket will be grafted with PRGF-Endoret

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABB
Description: After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
Study: NCT01382004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin-G-benzathine
Description: Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
Study: NCT02574013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoractor®
Description: Endoscopic sponge for retraction of small intestine
Study: NCT03398057

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Placebo health education (pamphlets) will be applied to this group participants during study.